title: Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia.
abstract: Imatinib has been considered as the gold standard for drug therapy of chronic myelogenous leukemia (CML) because it offers higher cytogenetic response and better quality of life than traditional drugs. In this study we applied the standard 400 mg dose of imatinib in 37 CML Ph (+) Mexican patients, monitoring their cytogenetic response using fluorescent in situ hybridization and carrying out molecular analyses using reverse transcription polymerase chain reaction. The study included 19 male and 18 female patients with a median age of 41 years. The median follow-up time from diagnosis was 56 months. Thirty-six patients (97%) achieved complete hematologic response in a median time of 29 days. Complete cytogenetic response and complete molecular remission was observed in only five (13%) and three (8.1%) patients, respectively, less than the expected rate (50-90%) reported in other studies.
authors: Servicio de Hematología, Hospital Universitario ‘Dr. José Eleuterio González’-UANL, Mexico.
authors: Cesar Homero
authors: CH
authors: Gutierrez-Aguirre
authors: Fernando
authors: F
authors: Garcia-Rodriguez
authors: Victor Manuel
authors: VM
authors: Ortiz-Galvez
authors: Olga Graciela
authors: OG
authors: Cantu-Rodriguez
authors: Rosario
authors: R
authors: Salazar-Riojas
authors: Odra Lizzette
authors: OL
authors: Martinez-Gonzalez
authors: Oscar
authors: O
authors: Gonzalez-Llano
authors: Jose Carlos
authors: JC
authors: Jaime-Pérez
authors: Rocio
authors: R
authors: Ortiz-Lopez
authors: Juan Antonio
authors: JA
authors: Flores-Jimenez
authors: Julio
authors: J
authors: Alatorre-Ricardo
authors: Consuelo
authors: C
authors: Mancias-Guerra
authors: David
authors: D
authors: Gomez-Almaguer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D003582:Cytogenetics; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008800:Mexico; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate